Sanaa, Yemen
Sanaa, Yemen

Saba University School of Medicine is a for-profit medical school located in The Bottom, Saba, a special municipality of the Netherlands in the Caribbean. Saba University confers upon its graduates the Doctor of Medicine degree. Saba University is owned by R3 Education, Inc. Wikipedia.


Time filter

Source Type

Chandramohan V.,Duke University | Bao X.,Duke University | Bao X.,Fudan University | Keir S.T.,Duke University | And 8 more authors.
Clinical Cancer Research | Year: 2013

Purpose: The EGF receptor gene (EGFR) is most frequently amplified and overexpressed, along with its deletion mutant, EGFRvIII, in glioblastoma. We tested the preclinical efficacy of the recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, which is reactive with a 55-amino acid (AA) region present in the extracellular domain of both EGFRwt (583-637 AAs) and EGFRvIII (292-346 AAs) proteins. Experimental Design: The binding affinity and specificity of D2C7-(scdsFv)-PE38KDEL for EGFRwt and EGFRvIII were measured by surface-plasmon resonance and flow cytometry. In vitro cytotoxicity of D2C7-(scdsFv)-PE38KDEL was measured by inhibition of protein synthesis in human EGFRwt-transfected NR6 (NR6W), human EGFRvIII-transfected NR6 (NR6M), EGFRwt-overexpressing A431-epidermoid-carcinoma, and glioblastoma xenograft cells (43, D08-0493MG, D2159MG, and D270MG). In vivo antitumor efficacy of D2C7-(scdsFv)-PE38KDEL was evaluated using 43, NR6M, and D270MG orthotopic tumor models. Results: The KD of D2C7-(scdsFv)-PE38KDEL for EGFRwt and EGFRvIII was 1.6 × 10-9 mol/L and 1.3 × 10-9 mol/L, respectively. Flow cytometry with NR6W and NR6M cells confirmed the specificity of D2C7-(scdsFv)-PE38KDEL for EGFRwt and EGFRvIII. The D2C7-(scdsFv)-PE38KDEL IC50 was 0.18 to 2.5 ng/mL on cells expressing EGFRwt (NR6W, A431, 43, and D08-0493MG). The D2C7-(scdsFv)-PE38KDEL IC 50 was approximately 0.25 ng/mL on EGFRvIII-expressing cells (NR6M) and on EGFRwt- and EGFRvIII-expressing glioblastoma xenograft cells (D2159MG and D270MG). Significantly, in intracranial tumor models of 43, NR6M, and D270MG, treatment with D2C7-(scdsFv)-PE38KDEL by convection-enhanced delivery prolonged survival by 310% (P = 0.006), 28% (P = 0.002), and 166% (P = 0.001), respectively. Conclusions: In preclinical studies, the D2C7-(scdsFv)-PE38KDEL immunotoxin exhibited significant potential for treating brain tumors expressing EGFRwt, EGFRvIII, or both. ©2013 AACR.


News Article | October 29, 2016
Site: www.prweb.com

Drs. Jules Monier, Elizabeth Coronado, Quyen Dang and Shuchi Desai welcome Dr. David Baghdassarian to the Women’s Specialists of Plano team serving patients in the Plano, Frisco and Dallas, Texas communities. Board certified in obstetrics and gynecology, Dr. Baghdassarian approaches each patient’s health as a partnership and is deeply committed to listening to his patients in order to provide the best possible medical care. Dr. Baghdassarian relocated from Bellevue, Washington in order to be closer to his wife’s family. Serving as a pregnancy doctor and Plano gynecologist, Dr. Baghdassarian provides care to women in all stages of life, including prenatal care, preventive care, menopause management and urinary incontinency. He also specializes in advanced minimally invasive, robotic and pelvic reconstructive surgery. In addition to English, Dr. Baghdassarian is also fluent in French. “Dr. B as I like to call him is such a great OB. He is very personable and really listens to his patients,” said patient Karlee W. “He makes you feel as if you're being heard which is sometimes all you need to feel at ease during your pregnancy.” Dr. Baghdassarian received his medical degree from Saba University School of Medicine in the Netherlands-Antilles and completed his residency in obstetrics and gynecology at New York Medical College. After he completed his residency, Dr. Baghdassarian began his practice at the University of Washington (UW) Medicine as an OBGYN in 2012. During his time there, he was awarded the UW Praise Award for his outstanding patient satisfaction rating and excellence in patient care. “Women are the nucleus of each and every family, thus their health and welfare is of utmost importance," said Dr. Baghdassarian. "Here at Women’s Specialists of Plano, my colleagues and I are committed to providing world class medicine to all our patients.” Women’s Specialists of Plano (WSOP) is a full service obstetrician-gynecologist practice that focuses on providing care from adolescent gynecology to menopause treatment for women in Plano, Frisco and North Dallas. The team of Plano OBGYN physicians and pregnancy doctors at WSOP strive to provide the most innovative treatment options to patients in North Texas. The Plano gynecologists at WSOP provide comprehensive obstetrics and gynecology services including minimally invasive surgical treatment such as da Vinci Robotic Surgery, a full range of laparoscopic and hysteroscopic procedures and in-office edometiral ablation.


Rana A.Q.,Parkinsons Clinic of Eastern Toronto and Movement Disorders Center | Ahmed U.S.,Ryerson University | Chaudry Z.M.,Saba University | Vasan S.,American University of Antigua
Expert Review of Neurotherapeutics | Year: 2015

Parkinson's disease (PD) is a neurodegenerative disorder resulting from degeneration of the substantia nigra and the dopaminergic nigrostriatal pathway. Most treatments are geared toward the management and relief of motor symptoms in Parkinson's patients; however, as the disease progresses, various complications can be observed. Non-motor symptoms (NMS) may arise simply from the disease itself and are highly destructive to quality of life. These symptoms include mood disorders, cognitive dysfunction, pain, sensory dysfunction, and dysautonomia. Though it is undisputed that many NMS may appear years or even decades prior to the clinical diagnosis of PD, the focus of this review will be the overt motor phase of the condition. As such, the focus of this paper is to review the major NMS found in PD patients status post-diagnosis, their etiology, as well as treatment options available for the individual NMS. © 2015 Informa Uk, Ltd.


Ouban A.,Saba University | Ahmed A.A.,Childrens Mercy Hospitals and Clinics
Histology and Histopathology | Year: 2010

Claudins are tight junction proteins that are critical for the sealing of cellular sheets and controlling paracellular ion flux. The claudin family of proteins is composed of at least 24 closely related transmembrane proteins, most of them are well characterized at the gene and protein levels. The claudins are present in variety of normal tissues, hyperplastic conditions, benign neoplasms, and cancers that exhibit epithelial differentiation. Loss of claudins expression has also been reported in several malignancies as well. Differential expression of various members of the claudins family in cancers can be used in confirming the histologic identity of certain cancers and excluding others. Examples include the use of immunohistochemical detection of claudins to differentiate between oncocytoma and chromophobe renal cell carcinoma, endometrial endometrioid carcinoma and seropapillary carcinoma, mesothelioma and metastatic adenocarcinoma, hepatocellular and biliary tract carcinomas, and between intestinal-type and diffuse-type gastric carcinoma. Expression of certain claudins can also be used as markers that can predict patient's prognosis. Thus, it seems that attempts to identify expression claudins in cancers are becoming increasingly useful in histologic diagnosis of tumors as well as means to assess patient's prognosis.


Rana A.Q.,Movement Disorders Center | Chaudry Z.M.,Saba University | Blanchet P.J.,University of Montréal
Drug Design, Development and Therapy | Year: 2013

The aim of this review is to assess new, emerging, and experimental treatment options for tardive dyskinesia (TD). The methods to obtain relevant studies for review included a MEDLINE search and a review of studies in English, along with checking reference lists of articles. The leading explanatory models of TD development include dopamine receptor supersensitivity, GABA depletion, cholinergic deficiency, neurotoxicity, oxidative stress, changes in synaptic plasticity, and defective neuroadaptive signaling. As such, a wide range of treatment options are available. To provide a complete summary of choices we review atypical antipsychotics along with resveratrol, botulinum toxin, Ginkgo biloba, tetrabenazine, clonaze- pam, melatonin, essential fatty acids, zonisamide, levetiracetam, branched-chain amino acids, drug combinations, and invasive surgical treatments. There is currently no US Food and Drug Administration-approved treatment for TD; however, prudent use of atypical antipsychotics with routine monitoring remain the cornerstone of therapy, with experimental treatment options available for further management. © 2013 Rana et al.


Visalakshi P.,LRS Institute of TB and Respiratory Diseases | Meharwal S.K.,Saba University | Myneedu V.P.,LRS Institute of TB and Respiratory Diseases | Behera D.,LRS Institute of TB and Respiratory Diseases
Diagnostic Microbiology and Infectious Disease | Year: 2010

The aim of this study was to evaluate a simple, rapid, and inexpensive colorimetric nitrate reductase assay (NRA) for direct drug susceptibility testing (DST) of Mycobacterium tuberculosis against rifampicin (RIF) and isoniazid (INH). A total of 118 smear-positive specimens were processed from patients on antituberculosis treatment. A comparison was made between the direct NRA of DST with the direct proportion method and with the internationally accepted indirect 1% proportion method as the "gold standard". The sensitivity and specificity of the direct NRA and indirect proportion method were 94% and 98%, and 100% and 98% for RIF and INH, respectively. Excellent agreement was found between the 2 tests with κ values of 0.92 and 0.98, and P value was less than 0.001 for RIF and INH. The results in most cases were available in 14 days (turnaround time). The direct NRA is a rapid, accurate, simple, and inexpensive method to determine multidrug resistance from sputum. Direct NRA may become an appropriate alternative method, especially for the resource poor settings. © 2010 Elsevier Inc. All rights reserved.


Alkabie S.,Saba University | Boileau A.J.,Saba University
World Neurosurgery | Year: 2016

Background Traumatic spinal cord injury (SCI) is a devastating neurologic entity characterized by a primary insult followed by a secondary pathologic cascade that propagates further injury. Hypothermia has an established clinical role in preventing SCI after cardiac arrest and thoracoabdominal aortic aneurysm repair, yet its emergence as a potential neuroprotectant after spinal cord trauma remains experimental. There are currently no pharmacologic interventions available to prevent secondary mechanisms of injury after spinal cord trauma. Methods Systematic review of literature. Results Experimental studies demonstrated that hypothermia diminishes secondary pathomechanisms, such as ischemia, oxidative stress, apoptosis, inflammation, and edema. Early onset and longer durations of hypothermia as well as concomitant steroids or neural stem cell engraftment combined with hypothermia appear to improve functional and histologic outcomes in animal models of spinal cord trauma. Recent clinical studies provide evidence that localized and systemic hypothermia may be applied safely and efficaciously in patients with severe acute SCI. Randomized clinical trials are needed to better evaluate optimal cooling parameters and the effectiveness of hypothermia after traumatic SCI. Conclusion Although variability exists in the literature, therapeutic hypothermia most likely confers neuroprotection after spinal cord trauma by diminishing the destructive secondary cascade. The available clinical data suggest that regional and systemic hypothermia is a relatively safe and feasible initial treatment modality for patients with acute SCI when combined with surgical decompression/stabilization with or without steroids. However, establishing a clinical role for therapeutic hypothermia after spinal cord trauma will invariably depend on future well-designed, multicentered, randomized, controlled clinical trial data. © 2016 Elsevier Inc. All rights reserved.


Mei-Dan O.,Saba University | Carmont M.R.,Princess Royal Hospital
Sports Medicine and Arthroscopy Review | Year: 2011

The shoulder is a common source of disability resulting from traumatic and degenerate tears of the rotator cuff, subacromial impingement, and osteoarthritis. Nonoperative management has focused on treatment of the predisposing factors, the use of analgesics and anti-inflammatory medication usually in association with local anesthetic and steroid injections. Surgical intervention allows debridement of the degenerate cuff and partial thickness cuff tears, subacromial bursitis, impinging bone spurs and osteophytes together with rotator cuff repairs. Repairs of degenerate and torn tissue are often prone to failure due to many intrinsic and extrinsic factors. It is assumed that some biological therapies might improve clinical, mechanical, and histologic outcomes. Injections of platelet-rich plasma (PRP) have led to reduced pain and improved recovery in other degenerate pathologies areas together with the restoration of function. This study reviews the current literature on PRP and in particular discusses its relevance in the treatment of rotator cuff tears. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Gorin D.R.,Cape Cod Hospital | Perrino L.,Cape Cod Hospital | Potter D.M.,Saba University | Ali T.Z.,Saba University
Journal of Vascular Surgery | Year: 2012

Objective: There has been an increasing awareness of the superiority of native arteriovenous fistulas (AVFs) over prosthetic grafts for dialysis access. Many AVFs fail to mature, however, and others develop stenosis while in use. There is growing experience in treating these patients in the interventional suite with percutaneous balloon angioplasty. These procedures, however, are expensive, uncomfortable, and inconvenient for patients and physicians, and involve exposure to radiation and intravenous contrast in patients who are often not on dialysis. This study reviews our experience with ultrasound-guided angioplasty of AVFs in the office setting. Methods: A retrospective review was performed of all patients treated in our practice with ultrasound-guided AVF angioplasty, from May 2009 to April 2011. The need for intervention was determined by examination and duplex ultrasound. All patients referred to the practice with failing or nonmaturing AVFs were treated in the office under ultrasound guidance, unless a central venous stenosis was suspected. All procedures were performed with the patient under local anesthesia by a single surgeon, and preprocedure, periprocedure, and postprocedure ultrasounds were performed in a single vascular laboratory. Results: There were 31 AVFs in 30 patients in the study. Fifty-five interventions were performed, 48 for AVFs failing to mature and seven for stenosis in functioning AFVs. The 90-day patency was 93%. The overall complication rate was 11%. Two patients had proximal stenosis that could not be crossed (one patient required surgical revision and one patient refused further treatment and thrombosed). There were four perifistular hematomas; three of these resulted in AFV thrombosis. No patients required hospitalization or urgent surgical intervention. Eighty-five percent of patients treated for AVF failing to mature achieved a functional fistula. Conclusions: AVF intervention can be performed safely and effectively under ultrasound guidance in the office setting and is a valuable tool in the management of dialysis access patients. © 2012 Society for Vascular Surgery.


Mei-Dan O.,Saba University | Carmont M.R.,Princess Royal Hospital | Laver L.,Saba University | Mann G.,Saba University | And 3 more authors.
American Journal of Sports Medicine | Year: 2012

Background: Nonoperative options for osteochondral lesions (OCLs) of the talar dome are limited, and currently, there is a lack of scientific evidence to guide management. Purpose: To evaluate the short-term efficacy and safety of platelet-rich plasma (PRP) compared with hyaluronic acid (HA) in reducing pain and disability caused by OCLs of the ankle. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: Thirty-two patients aged 18 to 60 years were allocated to a treatment by intra-articular injections of either HA (group 1) or PRP (plasma rich in growth factors [PRGF] technique, group 2) for OCLs of the talus. Thirty OCLs, 15 per arm, received 3 consecutive intra-articular therapeutic injections and were followed for 28 weeks. The efficacy of the injections in reducing pain and improving function was assessed at each visit using the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale (AHFS); a visual analog scale (VAS) for pain, stiffness, and function; and the subjective global function score.Results: The majority of patients were men (n = 23; 79%). The AHFS score improved from 66 and 68 to 78 and 92 in groups 1 and 2, respectively, from baseline to week 28 (P <.0001), favoring PRP (P <.05). Mean VAS scores (1 = asymptomatic, 10 = severe symptoms) decreased for pain (group 1: 5.6 to 3.1; group 2: 4.1 to 0.9), stiffness (group 1: 5.1 to 2.9; group 2: 5.0 to 0.8), and function (group 1: 5.8 to 3.5; group 2: 4.7 to 0.8) from baseline to week 28 (P <.0001), favoring PRP (P <.05 for stiffness, P <.01 for function, P >.05 for pain). Subjective global function scores, reported on a scale from 0 to 100 (with 100 representing healthy, preinjury function) improved from 56 and 58 at baseline to 73 and 91 by week 28 for groups 1 and 2, respectively (P <.01 in favor of PRP). Conclusion: Osteochondral lesions of the ankle treated with intra-articular injections of PRP and HA resulted in a decrease in pain scores and an increase in function for at least 6 months, with minimal adverse events. Platelet-rich plasma treatment led to a significantly better outcome than HA. © 2012 American Orthopaedic Society for Sports Medicine.

Loading Saba University collaborators
Loading Saba University collaborators